STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.
Revolution Medicines' pancreatic cancer drug Rasonque made a striking commercial debut, generating $198 million in sales within just five weeks of its U.S. approval. This groundbreaking pan-RAS inhibitor has already been administered to over 5,000 patients, according to information released by the company on Wednesday. Anthony Mancini, Revolution's Chief Commercial Officer, commented on the company's earnings call, stating that the launch of Rasonque is off to a strong start, a statement that could be considered an understatement of the year in commercial biotech.
The sales performance of Rasonque was nearly double the most optimistic investor projections before the company's third-quarter earnings announcement. While it may be premature to declare Rasonque the best cancer drug launch in history, it is certainly very close, prompting investors to reassess their forecasts for the future. For the complete story, continue to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
